Kent Doi

Kent Doi
Department of Emergency and Critical Care Medicine The University of Tokyo Tokyo, Japan Kent Doi, M.D., Ph.D. is Professor of Medicine in the department of Emergency and Critical Care Medicine at The University of Tokyo, Japan. He received his M.D. and Ph.D. at the University of Tokyo followed by research nephrology training at NIH/NIDDK. At the University of Tokyo, Dr. Doi is currently a clinical and basic research investigator. His research interests include acute kidney injury, sepsis, and multiple organ failure. His research involves AKI biomarker, sepsis-induced AKI, and organ system network analysis in multiple organ failure. Dr. Doi is a council member of the Japanese Society of Intensive Care Medicine, Fellow of the Japanese Society of Internal Medicine (FJSIM), Councilor and Board-Certified Nephrologist of the Japanese Society of Nephrology, Board Certified Senior Member of the Japanese Society for Dialysis Therapy. Dr. Doi has published over 300 scientific articles and has delivered over 40 presentations at scientific meetings. He is an Editorial board member for Kidney International and other journals.

19th September 2026 Saturday

Time Session
08:30
10:15
Plenary 1: Organ Dysfunction in the Critically Ill Patient: Emerging Concepts
Chih-Wei Yang Moderator
Room 1

20th September 2026 Sunday

Time Session
12:40
13:45
Lunch symposium: Polymyxin B Hemoadsorption in Sepsis
Shuei-Liong Lin Moderator
Yuh-Min Chen Moderator
  • Opening
  • Targeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
    Kent Doi Speaker Organ crosstalk in AKITargeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
  • From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?
    Yen-Ta Huang Speaker From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?Polymyxin B hemoadsorption has occupied an unusually contested place in sepsis care, and the way authoritative bodies describe it has shifted over time. This talk traces that evolution—from the 2020 Taiwan AKI consensus through the 2021 and 2026 Surviving Sepsis Campaign guidelines—and uses the changing recommendations as a lens on the methodological debates that underlie them. From an evidence-based medicine standpoint, the controversy is less about the device than about how we generate and grade evidence. I will first examine the frequentist evidence base, including our network meta-analysis of blood purification therapies for severe infection and sepsis/septic shock published in Critical Care Medicine. I will outline what a network meta-analysis adds—coherent ranking across multiple modalities, indirect comparison, and explicit quantification of heterogeneity—while being candid about its limitations, including reliance on the transitivity assumption, sparse networks, and the fragility of mortality estimates pooled from heterogeneous trials. I will then turn to the recently reported TIGRIS trial, which used a Bayesian, enrichment-based phase 3 design with prespecified borrowing from the EUPHRATES treatable cohort. I will highlight the strengths of the Bayesian presentation—direct posterior probabilities of benefit, transparent incorporation of prior evidence, and efficiency in a rare, mechanistically defined phenotype—alongside the cautions it demands: sensitivity to prior choice, the open-label design, and the gap between a high posterior probability and a confirmed effect. Bringing these strands together, the talk offers a multifaceted, methodology-driven reading of polymyxin B hemoadsorption in sepsis, and a transferable framework for clinicians facing the increasingly common situation in which guidelines, frequentist syntheses, and Bayesian trials appear to diverge.
  • Q&A
Room 2
16:00
17:30
Plenary 6: Emerging Strategies in AKI and Extracorporeal Support
Yu-Chang YEH Moderator
Room 1